

SEQENS

*Discover
your new group*

CONTINUUM OF PROGRESS

Together, a new adventure begins

WHY A NEW NAME?

A new name to:

- Bring together all our people and activities under the same name in order to create a strong sense of belonging between our various subsidiaries.
- Define a new brand positioning that corresponds better to the group's current activities and future evolution.
- Communicate under one banner internally and externally.
- Leverage Novacap's acquisitions in order to create a strong international group.

SEQENS: WHAT DOES IT MEAN?

Seqens refers naturally to its core synthesis activities mixed with the sequencing idea in which teams arrange molecules, competencies and technologies to take the science that accelerates progress to the next level.

Besides this, Seqens stands for three main aspects that illustrate the way the group leads its businesses:

SEQENS

[sɛkwəns]

WHY SEQENS?

Seqens carries in its writing and pronunciation the evocation of speed, strength and collectiveness, common in every language of our world.

1

Seqens for
SECONDS

progressive & accelerated processes to deliver quality ingredients on-time,

2

Seqens for
SEE & SEEK

a determined & ambitious vision to increase the level of research and service,

3

Seqens for
PERFORMANCE & HUMAN

advanced & controlled development of ecosystems where technologies and human skills bring together answers to the world's needs.

CONTINUUM OF PROGRESS

The Continuum of Progress is our conceptual approach of **seeing and doing things towards progress.**


It rhymes directly with our extensive pool of skills and technologies that creates value at each step and ensures a clear knowledge and vision of projects' evolution.

It crystallizes a snapshot of our group unique organisation, constantly capable of advising the diversity of clients and delivering on any product's stages with exemplary development standards with a worldwide scope.

CREATIVE INCARNATION

Our central brand idea, the Continuum of Progress, is visually translated with **linear sequences** that represent ingredients, ideas and skills all rigorously arranged **to draw a path to progress.**

They are captured in an **accelerated and active motion** that expresses the reactivity and accurate speed to market and the group's capabilities to understand challenges and deliver.



ALL OUR ACTIVITIES

SEQENS

SEQENS
COMO

SEQENS
ESSENTIAL DRUG SUBSTANCES

SEQENS
CUSTOM SPECIALTIES

SEQENS
R&D SERVICES

SEQENS
ADVANCED SPECIALTIES

SEQENS
SOLVENTS & PHENOL SPECIALTIES

SEQENS
MINERAL SPECIALTIES

SEQENS
ACID & DERIVATIVES

SEQENS
COSMETICS

ABOUT SEQENS

Seqens is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering outstanding performance, unrivalled market responsiveness and bespoke solutions to our customers.

Seqens' mission is to bring R&D and industrial performance to our clients' projects with a unique skill set and a broad continuum of technologies.

Seqens operates 24 industrial plants and 3 R&D centers in Europe, North America and Asia.

More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production. In the pharmaceutical industry, Seqens supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products.

Seqens also develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

Driven by a culture of excellence and a strong entrepreneurial spirit, Seqens' 3,200 employees are committed to providing its customers with the highest level of service and product quality while acting ethically in the frame of its Corporate Social Responsibility program.

SEQENS

21 CHEMIN DE LA SAUVEGARDE
«21 ECULLY PARC»
CS 33167
69134 ECULLY CEDEX
TEL. +33 04 26 99 18 00
FAX. +33 04 26 99 18 38

WWW.SEQENS.COM



SEQENS, A GLOBAL PLAYER



3200
people



300
scientists, experts
and engineers



24
manufacturing sites



3
R&D centers



1000
clients in more
than 80 countries